Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + TGFbDNRII-transduced autologous TILs|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Anti-NY ESO-1 mTCR PBL||NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL||Anti-NY ESO-1 mTCR PBL are peripheral blood lymphocytes that have been transduced with a retroviral vector expressing a T-cell receptor that targets NY-ESO, which may enhance anti-tumor immune response against NY-ESO-expressing tumor cells (PMID: 24598449).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|TGFbDNRII-transduced autologous TILs||TGFbDNRII-transduced autologous TILs are patient-derived tumor infiltrating lymphocytes engineered to express a dominant negative version of transforming growth factor beta receptor (TGFbDNRII), which potentially results in enhanced anti-tumor immune activity (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02650986||Phase Ib/II||Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + TGFbDNRII-transduced autologous TILs||Gene-Modified T Cells in Treating Patients With Locally Advanced or Stage IV Solid Tumors Expressing NY-ES0-1||Recruiting|